Advanced in High Potassium Level

Kieran Mccafferty

Charterhouse Square, 
London, ENG, GB 
Advanced in High Potassium Level
Charterhouse Square, 
London, ENG, GB 
OverviewLocationsClinical Research

Overview

Kieran Mccafferty practices in London, United Kingdom. Mr. Mccafferty is rated as an Advanced expert by MediFind in the treatment of High Potassium Level. His top areas of expertise are High Potassium Level, Chronic Kidney Disease, Diabetic Nephropathy, Kidney Transplant, and Nephrectomy.

His clinical research consists of co-authoring 66 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 7 articles in the study of High Potassium Level.

Gender
Male

Locations

Charterhouse Square, London, ENG, United Kingdom
Other Locations
Guy's and St Thomas' NHS Trust
London, ENG, United Kingdom

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

A Phase 2, Open-Label, Basket Study of Atrasentan in Patients With Proteinuric Glomerular Diseases
A Phase 2, Open-Label, Basket Study of Atrasentan in Patients With Proteinuric Glomerular Diseases
Enrollment Status: Active_not_recruiting
Publish Date: August 11, 2025
Intervention Type: Drug
Study Drug: Atrasentan
Study Phase: Phase 2
A Randomized, Multicenter, Double-blind, Parallel, Active-control Study of the Effects of Sparsentan, a Dual Endothelin Receptor and Angiotensin Receptor Blocker, on Renal Outcomes in Patients With Primary FSGS
A Randomized, Multicenter, Double-blind, Parallel, Active-control Study of the Effects of Sparsentan, a Dual Endothelin Receptor and Angiotensin Receptor Blocker, on Renal Outcomes in Patients With Primary FSGS
Enrollment Status: Active_not_recruiting
Publish Date: June 12, 2025
Intervention Type: Drug
Study Drugs: Sparsentan, Irbesartan
Study Phase: Phase 3
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Atrasentan in Patients With IgA Nephropathy at Risk of Progressive Loss of Renal Function
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Atrasentan in Patients With IgA Nephropathy at Risk of Progressive Loss of Renal Function
Enrollment Status: Active_not_recruiting
Publish Date: October 15, 2024
Intervention Type: Drug
Study Drug: Atrasentan
Study Phase: Phase 3
View 2 Less Clinical Trials

66 Total Publications

Artesunate alleviates kidney fibrosis by restoring klotho protein and suppressing Wnt/β-catenin signalling pathway.
Artesunate alleviates kidney fibrosis by restoring klotho protein and suppressing Wnt/β-catenin signalling pathway.
Journal: Frontiers in cell and developmental biology
Published: August 19, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Mccafferty's expertise for a condition
ConditionClose
      View All 18 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile